Physician profile
Christopher Keeley
NPI 1417914821
$2,731.81
in general payments reported to CMS, 2019-2025
26 companies · $339 in 2025
The $339 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $194 · 2020: $45.66 · 2021: $346 · 2022: $796 · 2023: $554 · 2024: $458 · 2025: $339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,351.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,351.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $418.59 | 2022-2025 | Slynd, Solosec |
| Minerva Surgical, INC | $361.95 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $342.81 | 2019-2025 | |
| Organon LLC | $276.25 | 2022-2025 | Nexplanon |
| Abbvie INC. | $228.18 | 2019-2023 | |
| Astellas Pharma US INC | $208.51 | 2022-2025 | Veozah |
| Amgen INC. | $137.71 | 2019-2025 | Evenity, Prolia |
| Hologic Sales and Service, LLC | $136.05 | 2019-2022 | |
| Novo Nordisk INC | $87.81 | 2019-2023 | Wegovy |
| Mayne Pharma Commercial LLC | $59.28 | 2022-2023 | |
| Biogen, INC. | $56.19 | 2025 | Zurzuvae |
| Tactile Systems Technology INC | $56.18 | 2022 | |
| Therapeuticsmd, INC. | $49.88 | 2019-2022 | |
| Myovant Sciences INC. | $44.00 | 2022 | |
| Pfizer INC. | $39.80 | 2023-2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $35.02 | 2021 | |
| Merck Sharp & Dohme LLC | $28.96 | 2019-2020 | |
| Vertex Pharmaceuticals Incorporated | $24.53 | 2024 | |
| Daiichi Sankyo INC. | $23.94 | 2025 | Injectafer |
| Convatec INC. | $22.37 | 2021 | |
| Dexcom, INC. | $19.79 | 2025 | Dexcom G6 Transmitter |
| Medtronic, INC. | $17.18 | 2024 | Ligasure |
| Amag Pharmaceuticals, INC. | $16.46 | 2019 | |
| Abbott Laboratories | $14.71 | 2023 | Proclaim |
| Sumitomo Pharma America, INC. | $13.78 | 2024 | Gemtesa |
| Avion Pharmaceuticals | $11.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Keeley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.